About Infliximab (REMSIMA)
Class: | Monoclonal antibody (TNF-alpha inhibitor)
Use: | Treatment of moderate to severe rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriasis, and hidradenitis suppurativa in adults; also used in pediatric patients for certain conditions.
Adult dose: | Initial dose: 160 mg (administered as 4 injections of 40 mg each at week 0), followed by 80 mg at week 2, then 40 mg every 2 weeks. For some conditions, dosing may vary based on clinical response.
Ped
Drug Class
Monoclonal antibody (TNF-alpha inhibitor)
Uses & Indications
Treatment of moderate to severe rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriasis, and hidradenitis suppurativa in adults; also used in pediatric patients for certain conditions.
Storage Requirements
Store in the refrigerator (2°C to 8°C). Do not freeze. Protect from light. Once removed from the refrigerator, it can be kept at room temperature (up to 25°C) for a maximum of 6 hours.
Manufacturer & Packaging
Manufacturer: HIKMA PHARMACEUTICALS CO.LTD, JORDAN
Package Size
1 Pre-filled pen (1 ml) with 2 alcohol pads
Price & Supplier
Price in UAE: AED 1943.00
Dosage Information
Adult Dose
Initial dose: 160 mg (administered as 4 injections of 40 mg each at week 0), followed by 80 mg at week 2, then 40 mg every 2 weeks. For some conditions, dosing may vary based on clinical response.
Pediatric Dose
For pediatric patients with Crohn's disease or ulcerative colitis, initial dose: 10 mg/kg (up to a maximum of 600 mg), followed by 5 mg/kg at weeks 2 and 6, then every 8 weeks.
Side Effects
Common side effects include injection site reactions, headache, nausea, abdominal pain, and increased risk of infections.
Contraindications & Precautions
Known hypersensitivity to infliximab or any component of the formulation; active infections (including tuberculosis); moderate to severe heart failure; and history of demyelinating disorders.
Important Warnings
Risk of serious infections (including tuberculosis), malignancies, and infusion-related reactions. Patients should be screened for tuberculosis prior to initiation. Caution in patients with a history of heart failure or demyelinating diseases. Regular monitoring is recommended.
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice.
Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication.
The information presented here is specific to medicines available in UAE pharmacies and is regularly updated
to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.